Health Trials

About this trial

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Post-Acute Sequelae of COVID (PASC, or "Long COVID") experience cognitive dysfunction. The investigators will test the hypothesis that 999 mL of IV saline will improve cognitive function in patients with POTS and Long COVID compared to placebo (50 mL of saline).

Eligibility criteria

Qualifiers

Patients with diagnosis of Long COVID

SARS-COV2 test positive

Symptoms > 12 weeks post COVID

Subjective complaint of 'brain fog" or cognitive dysfunction

Disqualifiers

Patients with overt causes for POTS (e.g., dehydration, prolonged bed rest)

An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.

Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.

Unable to give an informed consent.

Trial design

Treatments tested in this trial

  • IV normal saline (999 mL infusion)
  • IV normal saline (50 mL infusion)

Treatment groups

100 Participants
are divided into 2 treatment groups

Locations

1
University of CalgaryT2N 4Z6, CalgaryAlberta, Canada

Sponsors and collaborators

University of Calgary

Lead sponsor

Source ClinicalTrials.gov